Cantor Fitzgerald Reiterates Overweight on Arrowhead Pharma
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Arrowhead Pharma (NASDAQ:ARWR).
September 09, 2024 | 4:56 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated its Overweight rating on Arrowhead Pharma, indicating continued confidence in the company's stock performance.
The reiteration of an Overweight rating by a reputable analyst suggests a positive outlook for Arrowhead Pharma, likely leading to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100